Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.95 USD | +2.64% | +5.97% | +62.41% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.41% | 1.37B | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target